Brought to you by 
Gene therapy company bluebird bio acquires Precision Genome Engineering
18 Sep 2020
Executive Summary
Bluebird bio Inc. (gene therapy for genetic and orphan diseases) acquired Precision Genome Engineering Inc. (aka Pregenen; gene editing and cell signaling technologies) for 408.7k bluebird shares up front plus 94.1k shares held back for 18 months (together worth $19.2mm), and the assumption of $4.9mm of current liabilities.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gene therapy company bluebird bio acquires Precision Genome Engineering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice